Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | ENO1 | P06733 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434232 | 0.92 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL8716409 | 0.89 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL6840326 | 0.89 | ALDH1A1 (0.42) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL203641 | 0.89 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| Bis(Pivaloyloxymethyl) Succinate SCHEMBL3123390 | 0.89 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL4482845 | 0.89 | GAA (0.46) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL5534787 | 0.88 | PRKCA (0.43) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL8893353 | 0.87 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL8893364 | 0.87 | PRKCA (0.44) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL7373371 | 0.87 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | claimed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-5202462-A | Catalytic reaction of metal salt of pivalic acid with dihalomethane in presence of phase transfer catalyst | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-04-13 | — | — | US | claimed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | claimed |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-13 | — | — | US | disclosed |
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3177632-B1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | UNIV JOHNS HOPKINS (US) | 2022-01-12 | — | — | EP | disclosed |
| US-4427835-A | POLYMER BACKBONE WITH UNSATURATED PENDANT GROUPS, VINYL OR ALLYL ITACONATE | THE PROCTER & GAMBLE COMPANY (US) | 1984-01-24 | — | — | US | disclosed |
| US-4340603-A | N-(2-PHENYLETHYL)-W-PHENYLALKYLAMINES | INTERX RESEARCH CORPORATION (US) | 1982-07-20 | — | — | US | disclosed |
| US-4313956-A | Novel sypathomimetic amine prodrugs | INTERX RESEARCH CORP. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4311706-A | ADRENERGIC STIMULANTS | INTERX RESEARCH CORPORATION (US) | 1982-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | PRKCA 2966/4885BTN3A1 1897/4885ALDH1A1 796/4885 |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | PRKCA 2959/4885BTN3A1 1820/4885ALDH1A1 718/4885 |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | PRKCA 2966/4885BTN3A1 1897/4885ALDH1A1 796/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | PRKCA 3271/4885BTN3A1 2763/4885ALDH1A1 2794/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | PRKCA 1768/4885BTN3A1 3920/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.